From Sample to Insight: Technologies Driving the Future of Precision Oncology Assays
Diagnostic platforms that deliver rapid turnaround, are easy to use and provide clear, interpretable results are essential to achieving these timelines. Simplified workflows and user-friendly designs reduce delays at the point of testing and enable faster clinical decision-making. Managing Low-Quality or Limited Samples Oncology diagnostics frequently rely on technically challenging sample types such as formalin-fixed paraffin-embedded (FFPE) tissue, fine needle aspirates, and liquid biopsies. FFPE tissues are widely used in oncology pathology due to their compati- bility with histological workflows; however, the fixation process induces crosslinking and chemical modifications that degrade nucleic acids and can introduce sequencing artifacts. 3 Similarly, liquid biopsies, while minimally invasive and ideal for serial monitoring, often yield very low levels of circulating tumor DNA (ctDNA), mixed with abundant background cfDNA, 4 making it difficult to detect low- frequency variants with confidence. Clinical samples with a higher risk of PCR inhibi- tion often contain residual chemicals (e.g., form- aldehyde, ethanol), endogenous compounds (e.g., hemoglobin, heparin), or preservatives from blood collection tubes. These inhibitors can suppress enzyme activity, reduce amplification efficiency, and compromise result reliability. In low-input, high-sensitivity assays, such as minimal residual disease (MRD) monitoring or resistance mutation detection, trace levels of
PCR inhibitors may be sufficient to impact assay accuracy and reliability. Assays designed to tolerate PCR inhibitors are especially critical when tissue is scarce, repeat sampling is not possible, or when samples contain a low abundance of the target. To obtain clinically meaningful data under these conditions, assay accuracy and robustness in the presence of various inhibitors are essential. Standardization and Global Scalability Precision oncology requires a higher standard for reproducibility than most diagnostic fields because assay results directly influence treatment selection, trial eligibility, and longitudinal disease monitoring. To support this level of clinical impact, standard- ization across sites is essential. Without consistent reagent performance and protocol adherence, diagnostic drift can occur, 6 leading to variable clinical outcomes, compromised trial data integ- rity, and inequitable patient access to precision therapies. At the same time, the global expansion of precision oncology, fueled by international cancer initia- tives, multicenter trials, and decentralized care models, demands solutions that are operationally consistent across diverse laboratory settings and infrastructure levels. Addressing these demands requires assay formats that are scalable, easy to use, and analytically robust—delivering consistent performance across varied global settings to enable equitable access to high-quality oncology diagnostics.
30 | GENengnews.com
Powered by FlippingBook